Literature DB >> 9200010

Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis.

M Suarez-Almazor1, J E Homik, D Messina, P Davis.   

Abstract

The objective of this study was to evaluate the attitudes and beliefs of primary care physicians (PCPs) and obstetricians/gynecologists (O&Gs) in relation to the prevention and treatment of osteoporosis (OP) in postmenopausal women. A survey was mailed to a random sample of PCPs and to all O&Gs registered in the province of Alberta (Canada). The survey evaluated their practice patterns using closed-ended questions, Likert scaled items, and two case studies. Cases 1 and 2 were 52-year-old and 62-year-old healthy postmenopausal women, respectively, with no known risks for OP. Neither had received hormone replacement therapy (HRT). One hundred fifty-seven PCPs and 57 O&Gs participated in the study. Thirty-eight percent of the PCPs and 32% of the O&Gs stated that they never requested bone mineral density measurements (BMDm) in early postmenopausal women. Most would request BMDm only in the presence of risk factors. The most important criteria to request BMDm were chronic glucocorticoid use and recent fractures. For case 1, 7% of the PCPs and 11% of the O&Gs would request BMDm; 76% of the PCPs and 80% of the O&Gs would recommend HRT. For case 2, 29% of the PCPs and 47% of the O&Gs would request BMDm (p = 0.01); 43% of the PCPs and 49% of the O&Gs would prescribe HRT. In general, O&Gs were more inclined to intervene in relation to BMDm and HRT. O&Gs were also more likely to be influenced by clinical trials than PCPs (p < 0.001). Our findings show variations in the patterns of practice of physicians in relation to the prevention of OP. In general, use of densitometry appears to be low. The results of the case studies suggest that individual physician perceptions may be more influential than patient characteristics when requesting BMDm and prescribing HRT, particularly in older postmenopausal women. This group of healthy older women have approximately equal odds of being offered versus not being offered BMDm and HRT according to the physician they consult.

Entities:  

Mesh:

Year:  1997        PMID: 9200010     DOI: 10.1359/jbmr.1997.12.7.1100

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain.

Authors:  L Pérez-Edo; M Ciria Recasens; C Castelo-Branco; P Orozco López; A Gimeno Marqués; C Pérez; J Manasanch Dalmau
Journal:  Osteoporos Int       Date:  2004-01-27       Impact factor: 4.507

2.  Exploring the nurse practitioner role in managing fractures in long-term care.

Authors:  Sharon Kaasalainen; Alexandra Papaioannou; Jennifer Burgess; Mary Lou Van der Horst
Journal:  Clin Nurs Res       Date:  2015-03-29       Impact factor: 2.075

3.  Hormone replacement therapy: a survey of Ontario physicians' prescribing practices.

Authors:  L Elinson; M M Cohen; T Elmslie
Journal:  CMAJ       Date:  1999-09-21       Impact factor: 8.262

4.  Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study.

Authors:  T W Weiss; E S Siris; E Barrett-Connor; P D Miller; C A McHorney
Journal:  Osteoporos Int       Date:  2007-06-19       Impact factor: 4.507

5.  Ankle fracture configuration following treatment with and without arthroscopic-assisted reduction and fixation.

Authors:  Chayanin Angthong
Journal:  World J Orthop       Date:  2016-04-18

6.  Osteoporotic fracture: missed opportunity for intervention.

Authors:  Leah Port; Jacqueline Center; N Kathy Briffa; Tuan Nguyen; Robert Cumming; John Eisman
Journal:  Osteoporos Int       Date:  2003-08-07       Impact factor: 4.507

Review 7.  The osteoporosis care gap in Canada.

Authors:  A Papaioannou; L Giangregorio; B Kvern; P Boulos; G Ioannidis; J D Adachi
Journal:  BMC Musculoskelet Disord       Date:  2004-04-06       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.